Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

• Status: Not yet recruiting
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting trial (TOP-CABG trial) is a multicenter, randomized, double-blind, non-inferiority, parallel controlled trial. The first aim of TOP-CABG is to investigate, comparing to dual antiplatelet therapy (DAPT), whether de-escalated dual antiplatelet therapy (De-DAPT) is non-inferior to dual antiplatelet therapy (DAPT) in efficacy on inhibiting great saphenous vein (SVG) graft occlusion in patients accepting coronary artery bypassing grafting. The second aim is to compare the risk of bleeding events between DAPT and De-DAPT.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China National Center for Cardiovascular Diseases
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

• Patients who underwent planned CABG with ≥1 SVGs were eligible for inclusion

Exclusion Criteria:

• 1) Patients who underwent valvular surgery, arrhythmia and other cardiac operations at the same time as CABG surgery.

2) Acute coronary syndrome (ACS) patients. 3) patients with contraindications of multislice computed tomographic angiography or coronary angiography.

4) patients who take oral anticoagulants before operation and need to continue to take anticoagulants after operation.

5) patients who take oral P2Y12 inhibitors or other antiplatelet drugs before operation and cannot stop the drugs after operation.

6) patients with contraindications to antiplatelet therapy (history of allergy, intracranial hemorrhage, massive hemorrhage, gastrointestinal reactions caused by intolerance to antiplatelet drugs.

7) patients who had been implanted eluting stents within 6 months or bare metal stents within 1 month before CABG.

8) Thrombocytopenia before CABG